Budgetary impact analysis of a primary care-based hepatitis C treatment program: Effects of 340B Drug Pricing Program-Reference-Cited by-同舟云学术

Budgetary impact analysis of a primary care-based hepatitis C treatment program: Effects of 340B Drug Pricing Program

Published:2019-03-14 Issue:3 Volume:14 Page:e0213745
ISSN:1932-6203
Container-title:PLOS ONE
language:en
Short-container-title:PLoS ONE

Author:

Jones Eric A.,Linas Benjamin P.,Truong Ve,Burgess James F.,Lasser Karen E.^ORCID

Funder

National Institute on Drug Abuse

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference32 articles.

1. Chronic hepatitis C virus infection in the United States, National Health and Nutrition Examination Survey 2003 to 2010;MM Denniston;Ann Intern Med,2014

2. Changing trends in hepatitis C-related mortality in the United States, 1995–2004;M Wise;Hepatology,2008

3. National Institutes of Health. National Institutes of Health Consensus Development Conference statement Management of Hepatitis C: 2002 June 10–12, 2002. HIV Clin Trials. 2003;4:55–75.

4. Ledipasvir/sofosbuvir regimens for chronic hepatitis C infection: Insights from a work productivity economic model from the United States;ZM Younossi;Hepatology,2015

5. Expanding primary care capacity to treat hepatitis C virus infection through an evidence-based care model—Arizona and Utah, 2012–2014;K Mitruka;MMWR Morb Mortal Wkly Rep,2014

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Assessing provider knowledge of the federal 340B Drug Pricing Program in a federally qualified health center;American Journal of Health-System Pharmacy;2024-04-01

2. Assessing the Impact of the 340B Drug Pricing Program: A Scoping Review of the Empirical, Peer‐Reviewed Literature;The Milbank Quarterly;2024-01-28

3. Outcomes of the 340B Drug Pricing Program;JAMA Health Forum;2023-11-22

4. Evaluation of 340B prescription assistance program on healthcare use in chronic obstructive pulmonary disease;Exploratory Research in Clinical and Social Pharmacy;2023-09

5. 340B—Where Do We Go From Here?;JAMA;2023-08-15